

Severe Hypernatremia as Presentation of Netherton Syndrome

A. Di Nora¹ M.C. Consentino¹ G. Messina¹ T. Timpanaro¹ P. Smilari¹ P. Pavone¹

¹Department of Clinical and Experimental Medicine, University of Catania, Catania CT, Italy

Address for correspondence Alessandra Di Nora, Doctor of Medicine, Department of Clinical and Experimental Medicine, University of Catania, Catania CT, Italy (e-mail: alessandradinora@gmail.com).

Glob Med Genet 2023;10:335-338.

Abstract

Netherton syndrome is a rare, multisystem, autosomal recessive genodermatosis characterized by a triad of manifestations: congenital ichthyosis, immune dysregulation, and scalp anomalies. We report the case of a 1-month-old male infant evaluated for failure to thrive and feeding difficulties. At birth, the infant was admitted to intensive care for severe hypernatremia (natremia 186 mg/dL). Upon entering the ward, the general conditions were poor. He presented with diffuse erythrodermia. A dermatological evaluation showed evidence of "invaginated trichuriasis," a typical sign of Netherton syndrome. Netherton syndrome is caused by a genetic mutation causing loss of function of the SPINK5 gene it encodes for the LEKTI protein, normally expressed in epithelia. Loss of LEKTI induces severe skin barrier defect. The history of the disease is characterized by serious potential complications in the first months of life, such as the risk of hypernatremic dehydration induced by high skin permeability, recurrent and/or severe infections, and growth retardation.

Keywords

- hypernatremia
- genodermatosis
- Trichorrhexis invaginata

Introduction

Netherton syndrome (NS) is a rare, multisystemic, autosomal recessive genodermatosis characterized by a triad of manifestations: congenital ichthyosiform erythroderma, hair shaft abnormalities, and immune dysregulation. The incidence of the disorder is evaluated to be 1/200,000, and the prevalence is 1 to 9/1,000,000.^{1,2} The genetic defect involves a serine protease inhibitor Kazal-type 5 (SPINK5) gene, encoding lymphoepithelial Kazal-type–related inhibitor (LEKTI), expressed in hair follicles and the granular layer of the epidermis.^{3,4} Deficiencies or anomalies in LEKTI are responsible for an excessive serine protease activity, causing the premature stratum corneum detachment and defect of skin barrier function.^{3,4}

Comel in 1949 described one of the main characteristics of NS, namely, ichthyosis linearis circumflexa, that consists of pruritic polycyclic erythematous patches with a double-edged circinate or serpiginous scale.⁵ Later, Netherton in

DOI https://doi.org/ 10.1055/s-0043-1776983. ISSN 2699-9404. 1958 described the pathognomonic hair abnormality of NS, the trichorrhexis invaginata (bamboo hair).⁶ Since then, several years have passed and NS is still a diagnostic challenge for the clinicians. In addition, there are no specific therapies yet.⁷ An early diagnosis is crucial to start the correct management of these patients, due to a significant mortality in the first years of life.⁷ Thus, neonatologists and pediatricians should consider this rare but potentially fatal diagnosis in the clinical practice. Here, we report the case of a 1-month-old male infant, admitted to our center for failure to thrive and feeding difficulties. The perinatal history was characterized by hypernatremia and ichthyosiform erythroderma. The clinical features, the genetic analyses, and the actual management were also reported.

Case Report

A 1-month-old male infant was evaluated for failure to thrive and feeding difficulties. He was delivered at 36 weeks

© 2023. The Author(s).

This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Georg Thieme Verlag KG, Rüdigerstraße 14, 70469 Stuttgart, Germany

after pregnancy with SARS-CoV-2 infection at the third trimester and gestational diabetes treated with alimental diet. Familial and antenatal history was unremarkable. Parents declared to be not familiars. At birth, the infant did not have asphyxiation or jaundice. Birth weight was 2,580 g. After 3 days, he was admitted in the neonatal intensive care unit for dehydration and skin changes. Electrolytes analyses showed hypernatremia (186 mmol/L), treated with water replacement. A dermatological consilience revealed a desquamative erythroderma and subsequent seborrheic dermatitis. He was discharged at 2 weeks of life, with normal value of natremia and indication of breastfeeding. Two weeks later, he was admitted to our pediatric center "Policlinico G. Rodolico" in Catania, Italy. At the time of admission, the infant presented with diffuse erythroderma, skin coat with large areas of flaking that in the region of the scalp took on a crusty appearance with areas of alopecia. The subcutaneous tissue was poorly represented; muscle masses appeared hypotrophic and hypotonic. (rhythmic heart sounds, systolic murmur 2/6; flat abdomen of regular shape and volumes, treatable and painless; sensory awake valid crying, normal elicitable osteotendineous rotouleous reflex with axial and appendicular hypotonia; weight 2,670 g). Routine analyses revealed positive value of polymerase chain reaction, such as in systemic infections. Skin swabs were performed, revealing the presence of Pseudomonas aeruginosa. Treatment with Merrem and Teicoplanin was started, with a good response. A new dermatological consultation was performed, describing "abundant lamellar desquamation with the presence of skin aspects suggestive of circumflex linear ichthyosis." The video-dermatoscopic examination of the scalp revealed the presence of invaginated trichuriasis. Genetic analyses were performed, confirming the suspect of NS. It revealed the mutation c.238dup (p.Ala80fs) in homozygosis of SPINK5, localized on chromosome 5q32. Genetic analysis in the parents revealed the same mutation in heterozygosis in both.

Discussion

Netherton syndrome is caused by loss-of-function mutations in the SPINK5 gene coding for LEKTI, usually expressed in stratified epithelia.⁸ Loss of LEKTI induces a severe skin barrier defect. The history of the disease is characterized by potential severe complications in the first months of life, such as the risk of hypernatremic dehydration induced by high skin permeability, recurrent and/or severe infections, and failure to thrive.⁹ Jones et al in 1986 reported the occurrence of hypernatremia in two neonates with NS.¹⁰ Recently, in 2020 Bellon et al reported the clinical experience of a series of 43 children affected by NS. They found hypernatremia in 53.5% of the population, mostly children characterized by skin inflammation at birth.⁹ Neonatal hypernatremia is an uncommon finding and it has been frequently associated with breastfeeding failure and weight loss.^{10–12} In our case, the extreme hypernatremia could not fully be explained only by weight loss. Other differential diagnoses were salt poisoning (rare in a young infant), diarrhea, and polyuria (in cases of diabetes




Fig. 1 Proposal of a flowchart in cases of neonatal hypernatremia. ECF, extracellular fluid; FeNa, fractional excretion of sodium.

insipidus; **Fig. 1**) We believe that the combination of inadequate breast milk and excess water losses due to the congenital erythroderma was the direct cause in our case.

Clinically, the evaluation under the microscope or with trichoscopy revealed the pathognomonic sign of trichorrhexis invaginate, giving the doubt of NS. In addition, failure to thrive was a confirmation of systemic substance pathology. Genetic analysis confirmed the clinical suspect, revealing the mutation c.238dup (p.Ala80fs) in homozygosis of SPINK5, localized on chromosome 5q32 (►Fig. 2). As reported in ClinVar, this sequence change creates a premature translational stop signal (p.Ala80Glyfs*19) in the SPINK5 gene, causing an absent or disrupted protein product. This variant is present in population databases (rs766893577, ExAC 0.002%) and it has been observed in several individuals affected with NS (PMID: 22089833, 25917539, 16628198, 10835624).^{13–17} In our case, the genetic analysis in both parents revealed the variant in heterozygosis. As reported in literature, genetic analysis in NS is mandatory not only for the diagnosis but also for the management and the prognosis.^{9,18} In fact, the various SPINK5 mutations are associated with organ-specific expression profiles for the various isoforms of LEKTI. Sarri et al conducted an interesting study analyzing the relationship between genotype and phenotype in patients with NS.¹⁸ They concluded that mutations located more upstream in LEKTI will produce a more severe phenotype than similar mutations located toward the 3' region.¹⁸ About the genetic mutation of our proband, in literature it has been correlated to the increased susceptibility to skin carcinomas, with a high association between HPV and nonmelanoma skin cancers.¹⁶




Fig. 2 Modified from SFARI genes, you can see SPINK5 involved with high confidence.

Infections are often reported in patients with NS. Bellon et al found cutaneous bacterial infections (mainly *Staphylococcus aureus* and *Pseudomonas aeruginosa*) in 27 among 43 children affected by the disease.⁹ It emphasizes that NS is a systemic genodermatosis that requires rigorous care procedures especially in the first year of life. In addition, comorbidities such as gastrointestinal, endocrinal, pulmonary involvement are reported in literature, with high incidence of severe metabolic anomalies.⁹ The failure to thrive and chronic non-infectious diarrhea, observed in severe NS forms, might be partly related to abnormal digestive permeability and absorption as SPINK5 mRNAs are expressed in the gastrointestinal tract.^{19,20}

About the management, in literature hydration up to >300 mL/kg/day is recommended, instead up to $\sim 160 \text{ mL/kg/day}$ in healthy newborn.⁹ Increased calorie and protein needs for adequate growth were required in the most severe patients (220 kcal/kg/day and 5 g/kg/day, respectively, compared to 90–110 kcal/kg/d and 1–2 g/kg/d in the healthy newborn).⁹ In a recent guideline, recommended treatment is topical therapy. Emollients are indicated at least two times a day and after bathing.²¹ Multiple advances in novel therapies for NS are currently in progress. Because of the known increased activity of KLK 5 in NS, several specific inhibitors of KLK 5 are under development.²²

Conclusions

NS is a rare genodermatosis. Its early diagnosis is important to start the best management. Hypernatremia and systemic infections are possibly fatal complications. Trichoscopy is an accessible and noninvasive auxiliary diagnostic tool in cases of doubt. Genetic test is mandatory for the diagnosis and useful to define the prognosis of the patient affected.

Conflict of Interest

None declared.

References

- 1 Mallory SB, Krafchik BR. What syndrome is this? Pediatr Dermatol 1992;2:157–160
- 2 Roda Â, Mendonça-Sanches M, Travassos AR, Soares-de-Almeida L, Metze D. Infliximab therapy for Netherton syndrome: a case report. JAAD Case Rep 2017;3(06):550–552
- 3 Shi ZR, Xu M, Tan GZ, Wang L, Guo Q, Tang ZQ. A case of Netherton syndrome with mutation in SPINK5 and FLG. Eur J Dermatol 2017; 27(05):536–537
- 4 Briot A, Lacroix M, Robin A, Steinhoff M, Deraison C, Hovnanian A. Par2 inactivation inhibits early production of TSLP, but not cutaneous inflammation, in Netherton syndrome adult mouse model. J Invest Dermatol 2010;130(12):2736–2742
- 5 Comel M. [Ichthyosis linearis circumflexa]. Dermatologica 1949; 98(03):133–136

- 6 Netherton EW. A unique case of trichorrhexis nodosa; bamboo hairs. AMA Arch Derm 1958;78(04):483–487
- 7 Orphanet: Comel Netherton Syndrome (2008). Accessed November 18, 2020 at: https:// www.orpha.net/consor/cgi-bin/Disease_Search.php? lng=EN&data_id=938&Disease_Disease_Search_diseaseType= =ORPHA&Disease_Disease_Search_diseaseGroup=634&Disease(s)/group%20of%20diseases=Comel-Nethertonsyndrome& title=Comel-Netherton-syndrome&search=Disease_Search_Simple
- 8 Bitoun E, Chavanas S, Irvine AD, et al. Netherton syndrome: disease expression and spectrum of SPINK5 mutations in 21 families. J Invest Dermatol 2002;118(02):352–361
- 9 Bellon N, Hadj-Rabia S, Moulin F, et al. The challenging management of a series of 43 infants with Netherton syndrome: unexpected complications and novel mutations. Br J Dermatol 2021; 184(03):532–537
- 10 Jones SK, Thomason LM, Surbrugg SK, Weston WL. Neonatal hypernatraemia in two siblings with Netherton's syndrome. Br J Dermatol 1986;114(06):741–743
- 11 Oddie SJ, Craven V, Deakin K, Westman J, Scally A. Severe neonatal hypernatraemia: a population based study. Arch Dis Child Fetal Neonatal Ed 2013;98(05):F384–F387
- 12 Panagoda R, De Cure N, McCuaig R, Kent AL. Neonatal hypernatraemic dehydration. J Paediatr Child Health 2015;51(06):653–654
- 13 Lacroix M, Lacaze-Buzy L, Furio L, et al. Clinical expression and new SPINK5 splicing defects in Netherton syndrome: unmasking a frequent founder synonymous mutation and unconventional intronic mutations. J Invest Dermatol 2012;132(3, Pt 1):575–582
- 14 Descargues P, Deraison C, Prost C, et al. Corneodesmosomal cadherins are preferential targets of stratum corneum trypsin-

and chymotrypsin-like hyperactivity in Netherton syndrome. J Invest Dermatol 2006;126(07):1622–1632

- 15 Chavanas S, Bodemer C, Rochat A, et al. Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat Genet 2000;25(02):141–142
- 16 Guerra L, Fortugno P, Sinistro A, et al. Betapapillomavirus in multiple non-melanoma skin cancers of Netherton syndrome: case report and published work review. J Dermatol 2015;42(08):786–794
- 17 National Center for Biotechnology Information ClinVar [VCV000459573.6]. Accessed December 19, 2021 at: https:// www.ncbi.nlm.nih.gov/clinvar/variation/VCV000459573.6
- 18 Sarri CA, Roussaki-Schulze A, Vasilopoulos Y, et al. Netherton syndrome: a genotype-phenotype review. Mol Diagn Ther 2017; 21(02):137–152
- 19 Tartaglia-Polcini A, Bonnart C, Micheloni A, et al. SPINK5, the defective gene in Netherton syndrome, encodes multiple LEKTI isoforms derived from alternative pre-mRNA processing. J Invest Dermatol 2006;126(02):315–324
- 20 Herz-Ruelas ME, Chavez-Alvarez S, Garza-Chapa JI, Ocampo-Candiani J, Cab-Morales VA, Kubelis-López DE. Netherton syndrome: case report and review of the literature. Skin Appendage Disord 2021;7(05):346–350
- 21 Mazereeuw-Hautier J, Vahlquist A, Traupe H, et al. Management of congenital ichthyoses: European guidelines of care, part one. Br J Dermatol 2019;180(02):272–281
- 22 Zingkou E, Pampalakis G, Sotiropoulou G. Cathelicidin represents a new target for manipulation of skin inflammation in Netherton syndrome. Biochim Biophys Acta Mol Basis Dis 2020;1866(10): 165831